Product Details
| Product Name: Lanreotide | CAS No.: 127984-74-1 |
| Min. Order: 1KG | Purity: 99% |
| Supply Ability: 1T | Release date: 2025/10/22 |
| Product Name: | Lanreotide Acetate |
| Synonyms: | 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide;Somatulina;LANREOTIDE ACETATE;3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate;Angiopeptin acetate;10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide;Lanreotide Acetate USP/EP/BP;10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)a... |
| CAS: | 127984-74-1 |
| MF: | C54H69N11O10S2 |
| MW: | 0 |
| EINECS: | |
| Product Categories: | Amino Acids & Derivatives, Pharmaceuticals, Intermediates & Derivatives |
| Mol File: | 127984-74-1.mol |
 | |
| Lanreotide Acetate Chemical Properties |
| Melting point | >165°C (dec.) |
| storage temp. | -20°C |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | powder |
| color | white to off-white |
| InChIKey | PUDHBTGHUJUUFI-UHFFFAOYSA-N |
| SMILES | S1CC(NC(=O)C(N)CC2=CC=C3C(=C2)C=CC=C3)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2C3=C(NC=2)C=CC=C3)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(C(NC(C(=O)N)C(O)C)=O)CS1 |
| Safety Information |
| Hazard Codes | Xn |
| Risk Statements | 63 |
| Safety Statements | 36/37 |
| WGK Germany | 3 |
| MSDS Information |
| Lanreotide Acetate Usage And Synthesis |
| Description | Lanreotide acetate, an octapeptide somatostatin analog, reached its first worldwide market in France for acromegaly when surgery or radiotherapy have failed to restore normal growth hormone secretion. Lanreotide is a selective inhibitor of growth hormone and reduces the secretion of growth hormone, thyrotropin, motilin and pancreatic polypeptide in humans. Lanreotide has antiproliferative properties and is reportedly in clinical trials for the prevention of restenosis following coronary artery angioplasty, for diabetic retinopathy, and as a therapy for psoriasis. Its potential for neuroendocrine tumors and hormone-responsive prostate cancer has also been demonstrated. |
| Originator | Beaufour-Ipsen (France) |
| Uses | Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice. It is a drug used in the control and prevention of glycemia and hypoglycemic brain damage without surgery in patients diagnosed with congenital hyperinsulinism. It improves outcomes in patients suffering from acromegalyresulting from invasive pituitary macroadenoma. |
| Brand name | Somatuline LP |
| Biochem/physiol Actions | Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors. |
| Clinical Use | Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007. Lanreotide acetate is available in two formulations: a sustained release formulation (sold under the trade name Somatuline LA) and an extended release formulation (UK trade name Somatuline Autogel, or Somatuline Depot in the U.S.). In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes TSH. Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent. |
| Side effects | The side effects of Lanreotide Acetate include: Blurred vision; chest pain or discomfort; dizziness; gaseous abdominal or stomach pain; headache; lightheadedness, dizziness, or fainting; nervousness; pale skin; pounding in the ears; recurrent fever; slow, fast, or irregular heartbeat; stomach fullness; troubled breathing with exertion; unusual bleeding or bruising; unusual tiredness or weakness; yellow eyes or skin. |
Company Profile Introduction
Shandong Hanjiang Chemical Co., Ltd. is located in Zibo City, Shandong Province, China.
It is a biotechnology enterprise engaged in the R&D, production and sales of drugs, steroids, peptides, raw materials, vitamins, food additives, animal and plant extracts, cosmetics, pharmaceutical raw materials and intermediates. The company has complete experimental facilities. Advanced testing instruments ensure the stability of product quality from all aspects. The company has a complete sales service system, and its products are exported to countries all over the world. It has won a good international reputation for its excellent quality and excellent service. The company has been adhering to the basic principles of "integrity, quality, service, and win-win" to serve customers, and constantly strict requirements,
Advantages:
1. Samples are provided for test;
2. Good quality products;
3. 100% secure delivery.
4. secure your money, lower the risk
Payment ways: Western Union, Moneygram, Bitcoin, T/T
Delivery: EMS/ EUB/ USPS/ UPS/ TNT/ FEDEX/ DHL etc
Packaging:safe and discreet packaging
Our company Superiority
1 Best service, high quality and reasonable price
2. It's customers' right to choose the package (EMS, DHL, FedEx, UPS);
3. It's customers' right to choose the packing way for his products from many recent effective packing ways
4. Specials are possible when client's order is big enough, including the discount policy;
5.Our company promise to deliver clients' package to his hands safely, or we'll cover the total loss and reship in time;
Our company supply high quality chemical products with the most competitive prices.
If have any need or question, contact us freely.
Hope we can have chances to build good long-term cooperation.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1000.00/1g |
VIP1Y
|
Chengdu Shengnuo Biopharm Co.,Ltd
|
2025-09-19 | |
| $0.00/1kg |
VIP1Y
|
Jinan Ruitong Biotech Co., Ltd.
|
2025-08-22 | |
| $2.00/100kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-06-17 | |
| $1.00/1Piece |
VIP3Y
|
Wuhan Haorong Biotechnology Co.,Ltd
|
2025-03-20 | |
| $0.00/1Box |
Shanghai Affida new material science and technology center
|
2024-04-11 | ||
| $1.00/1g |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2024-03-26 | |
| $70.00/1kg |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-11-27 | |
| $286.00/1g |
Hebei Anlijie Biotechnology Co., Ltd
|
2023-09-01 | ||
| $35.00/1kg |
Hebei Xinsheng New Material Technology Co., LTD.
|
2023-08-22 | ||
| $0.00/25KG |
VIP6Y
|
Sichuan Zhuoyu Yantang Technology Co., Ltd.
|
2023-05-19 |
China- Since: 2020-06-09
- Address: Zibo City, Shandong Province, China Store Homepage Personal Center Follow Us Store Information Zhang
INQUIRY